Boston Scientific accounts are for healthcare professionals only.
Sustained therapy
Designed with over two decades of elution engineering experience, it is the only DES designed to deliver PTX when restenosis is most likely.
Proven results
With more than 6,000 Eluvia patients studied globally, the data provides proven evidence you can trust.
Consistent outcomes
Repeatable performance across long complex lesions in both RCTs and real world evidence.
Sustained
Sustained Drug Delivery Through the Restenosis Window
Eluvia DES releases paclitaxel for ~365 days. In comparison - Zilver PTX, a drug-coated stent without a polymer, releases all paclitaxel within 72 hours and paclitaxel is detectable in tissue through only 56 days.2
Eluvia's sustained approach is designed to support durability beyond the initial healing phase. Together, the release profile, critical restenosis window, and dose comparison highlight a treatment strategy focused on maintaining meaningful therapeutic activity over time rather than short-term drug intensity.
Proven
With extensive clinical evaluation across multiple studies, Eluvia offers evidence you can trust. Its outcomes are not only positive, but well-established and meaningfully differentiated—providing confidence when selecting therapy for challenging SFA disease.
Read more on clinical trials:
Consistent
Eluvia outcomes are consistent across all our clinical data
Eluvia DES vs. Zilver PTX 1 Year Primary Patency and Average Lesion Length5-20
Eluvia DES
96.4% MAJESTIC14 | 85.4% EMINENT RCT11 | 92.1% IMPERIAL RCT6 | 92.2% REGAL15 | 94.0% AUCKLAND16 | 91.0% IMPERIAL LL17 | 88.0% CAPISCUM18 | 91.0% DESAFINADO19 | 94.0% (full coverage) MÜNSTER20 | 85.8% ULTIMATE21 | 88.2% SPORTS22
Zilver PTX
83.1% ZILVER PTX RCT23 | 91.0% BATTLE24 | 81.8% IMPERIAL ZPTX6 | 86.2% ZILVER PTX (Single-Arm)25 | 79.9% REAL-PTX26 | 63.0% ZEPHYR27 | 77.6% ZILVER PTX (Single-Arm TASC C/D)28 | 52.5% STELLA29
Eluvia DES VS. Bare Metal Stents (BMS) 1 Year Primary Patency and Average Lesion Length5-15,22-26
Eluvia DES
96.4% MAJESTIC14 | 85.4% EMINENT RCT11 | 92.1% IMPERIAL RCT6 | 92.2% REGAL15 | 94.0% AUCKLAND16 | 91.0% IMPERIAL LL17 | 88.0% CAPISCUM18 | 91.0% DESAFINADO19 | 90.0% MÜNSTER20 | 85.8% ULTIMATE21 | 88.2% SPORTS22
BMS
72.6% COMPLETE SE30 | 76.3% EMINENT RCT11 | 71.2% STROLL SMART STENT31 | 86.3% SUPERB SUPERA32 | 77.2% DURABILITY33 | 82.1% SUPERA 500 MEDIUM34 | 81.8% SUPERA/BIOMIMICS META35 | 80.5% Supera 500 Long34 | 64.8% DURABILITY 20036
Eluvia has demonstrated consistent outcomes across a broad range of lesion lengths and patient complexity, helping reduce uncertainty in treatment planning and supporting confidence in more predictable results for real-world SFA disease.
References:
*Data on file at Boston Scientific. DRG US hospital market data, June 2025.
1. Iida, O. et al. Catheterization and Cardiovascular Interventions. 2011; 78:611–617.
2. Based on pre-clinical PK analysis for Zilver PTX. (Dake MD, et al. J Vasc Interv Radiol. 2011;22(5):603-610);
3. IN.PACT Pacific, Lutonix and Ranger DCBs (GongoraCA, et al. JACC Cardiovasc Interv. 2015 Jul;9(8):1115–1123. doi: 10.1016/j.jcin.2015.03.020.);
4. Eluvia (Müller-Hülsbeck S. Expert Opin Drug Deliv.2016 Oct 5:106.)
5. Data on file at Boston Scientific.
6. Gray, W. 2 year Outcomes from the IMPERIAL Randomized Head to Head Study of Eluvia DES and ZilverPTX. LINC 2020.
7. Gray WA, et al; A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, noninferiority trial. 1-Year Results. The Lancet. 2018 Oct 27;392(10157):1541-1551. doi: 10.1016/S0140-6736(18)32262-1. Epub 2018 Sep 24. PMID: 30262332.
8. Drug Dose Data from Eluvia DES, Zilver PTX, Lutonix 018 DCB, Lutonix 035 DCB, Stellarex 035 DCB, Surveil 035 DCB and Ranger DCB Instructions for Use. Data on file at Boston Scientific.
9. Gouëffic Y, Smith AB, Distler F, Lissina A, Hafermann J, Saunders R, Holden A, Steiner S. Performance of stenting in femoropopliteal disease: a systematic literature review and meta-analysis of proportions. J Comp Eff Res. 2026 Apr;15(4):e250152. doi: 10.57264/cer-2025-0152. Epub 2026 Mar 10.
10. SPORTS Tepe, G.Charing Cross 2026
11. EMINENT Gouëffi c Y, et al. Circulation. 2022;146(21):1564–1576.
12. Müller-Hülsbeck S, et al. Two-Year Efficacy and Safety Results from the IMPERIAL Randomized Study of the Eluvia Polymer-Coated Drug-Eluting Stent and the Zilver PTX Polymer-free Drug-Coated Stent. Cardiovasc Intervent Radiol. 2021;44(3):368-375. doi:10.1007/s00270-020-02693-1
13. Gray WA, et al. Polymer-based drug-eluting stent treatment extends the time to reintervention for patients with symptomatic femoropopliteal artery disease: clinical evidence and potential economic value. J Comp Eff Res. 2024;13(6):e240025. doi:10.57264/cer-2024-0025
14. MAJESTIC Müller-Hülsbeck S, et al. Cardiovasc Intervent Radiol. 2017;40(12):1832–1838
15. REGAL Lansink W, LINC 2023.
16. AUCKLAND Holden A, LINC 2020.
17. IMPERIAL LL Golzar J, et al. J Endovasc Ther. 2020;27(2):296–303.
18. CAPSICUM Iida O, et al. JACC Cardiovasc Interv. 2022;15(6):630–638.
19. DESAFINADO Kum S, et al. Vasc Med. 2021;26(3):267–272. 91% corresponds with the DESAFINADO “complete lesion coverage” subgroup.
20. MUNSTER Stavroulakis K, et al. JACC Cardiovasc Interv. 2021;14(6):692–701. 21. ULTIMATE Ichihashi S, et al. Eur J Vasc Endovasc Surg.2022;64(4):359–366. 22. Tepe G, CX 2025
23. ZILVER PTX RCT Dake MD, et al. Circulation. 2016 Apr 12;133(15):1472–83.
24. BATTLE Gouëffic Y et al. JACC Cardiovasc Interv. 2020 Feb 24;13(4):447–457.
25. Zilver PTX Single Arm Dake MD, et al. J Endovasc Ther 2011;18:613–23.
26. REAL PTX Bausback Y, et al. J Am Coll Cardiol. 2019 Feb19;73(6):667–679.
27. ZEPHYR Iida O, et al. JACC Cardiovasc Interv.2015 Jul;8(8):1105–1112.
28. ZILVER PTX Bosiers M, J Cardiovasc Surg (Torino). 2013 Feb;54(1):115–22.
29. STELLA PTX Davaine JM, et al. Eur J Vasc Endovasc Surg. 2015 Nov;50(5):631–7
30. COMPLETE SE J Endovasc Ther. 2014 Apr;21(2):202–12. doi: 10.1583/13-4548R.1
31. Gray WA, et al. S.M.A.R.T. Self-Expanding Nitinol Stent for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery (Stroll): 1-Year Outcomes. Journal of Vascular and Interventional Radiology (JVIR).2015;26(1):21–28.
32. SUPERB Laird et al (2012) Endovasc Ther. 2012; 19:1–9
33. Bosiers M, JVS 2011.
34. Werner M, EuroInt 2014.
35. Messeder SJ, et al. Eur J Vasc Endovasc Surg. 2024;67(3):468-479. 36. Matsumura JS, JVS 2014